Pembrolizumab (Keytruda) vastly improved development-free survival (PFS) over brentuximab vedotin (Adcetris) for Hodgkin’s lymphoma sufferers who failed on or were ineligible for transplant, findings from…
Pembrolizumab (Keytruda) vastly improved development-free survival (PFS) over brentuximab vedotin (Adcetris) for Hodgkin’s lymphoma sufferers who failed on or were ineligible for transplant, findings from…